Exploring Aging Drugs and Longevity Interventions

The chapter delves into the potential of aging drugs like Ozempic to impact various health conditions beyond their primary use, with a focus on addressing obesity-related aging. It discusses the distinction between medications targeting specific health issues and true aging interventions aiming to influence the underlying molecular aging processes for a broader population. The conversation also highlights the evolving landscape of partnerships and acquisitions between big pharma companies, aging-focused startups, and venture funds in the pursuit of innovative therapeutics for aging.